Germany's Carl Zeiss Meditec H1 revenue falls

Carl Zeiss Meditec AG

12/05/2026 06:43

Overview

Germany medical technology firm's fiscal H1 revenue fell 5.7% yr/yr

Adjusted EBITA and margin declined due to currency effects and unfavorable product mix

Outlook

Carl Zeiss Meditec expects 2025/26 revenue of at least €2.15-2.20 bln

Company forecasts 2025/26 adjusted EBITA margin of 8-10%, excluding special items

Result Drivers

NEGATIVE CURRENCY EFFECTS - Co said significant negative currency effects weighed on revenue and earnings

WEAK INVESTMENT CLIMATE - Co cited a weak investment climate, especially in the Americas, amid geopolitical uncertainty

PRODUCT AND DEVICE ISSUES - Exclusion of bifocal intraocular lenses from tenders, product recall, and lower device shipments affected Ophthalmology unit

Company press release: ID:nEQ4GjH46a

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
H1 Revenue
EUR 991 mln


Analyst Coverage

The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 2 "strong buy" or "buy", 16 "hold" and 1 "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy."

Wall Street's median 12-month price target for Carl Zeiss Meditec AG is €31.00, about 21.3% above its May 11 closing price of €25.56

The stock recently traded at 15 times the next 12-month earnings vs. a P/E of 15 three months ago

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)